Journal of Lipid Research
Volume 60, Issue 1, January 2019, Pages 212-217
Journal home page for Journal of Lipid Research

Methods
Lysophospholipid G protein-coupled receptor binding parameters as determined by backscattering interferometry[S]

https://doi.org/10.1194/jlr.D089938Get rights and content
Under a Creative Commons license
open access

Lysophosphatidic acid (LPA) activates cognate G protein-coupled receptors (GPCRs) to initiate biological signaling cascades. Lysophospholipid (LP) receptor binding properties remain incompletely assessed because of difficulties with ligand lipophilicity and lipid “stickiness.” These inherent attributes produce high levels of nonspecific binding within cell-membrane preparations used to assess GPCRs, as has been shown in classical binding assays using radiolabeled ligands, making accurate measurements of lipid binding kinetics difficult to achieve. Backscattering interferometry (BSI) is an optical technology that measures molecular binding interactions by reporting changes in the refractive index of a solution after binding events. Here, we report the use of BSI to assess LPA1 for its ability to bind to naturally occurring lipids and a synthetic LPA1 antagonist (ONO-9780307), under both primary- and competition-binding conditions. Assessment of 12 different lipids demonstrated that the known LP ligand, 1-oleoyl-LPA, as well as an endocannabinoid metabolite, anandamide phosphate, are specific ligands for LPA1, whereas other LPs tested were not. Newly determined dissociation constants (Kd values) for orthosteric lipid ligands approximated 10−9 M, substantially lower (i.e., with higher affinity) than measured Kd values in classical binding or cell-based assays. These results demonstrate that BSI may have particular utility in assessing binding interactions between lipid receptors and their lipid ligands and could provide new screening approaches for lipid receptor identification and drug discovery.

lipid
phospholipids
endocannabinoid
optical measurement
molecular interaction
binding assay

Cited by (0)

This work was supported by a grant from Ono Pharmaceutical Co., Ltd. and National Institute of Neurological Disorders and Stroke Grant R01 NS084398 (J.C.), and fellowships from the Uehara Memorial Foundation, the Kanae Foundation for the Promotion of Medical Science, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, and the Human Frontier Science Program, and National Institutes of Health Grant R01 NS103940 (Y.K.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

    Abbreviations:

    1-oleoyl-LPA

    1-oleolyl-lysophosphatidic acid

    AEAp

    anandamide phosphate

    BSI

    backscattering interferometry

    FFT

    fast Fourier-transformed

    GPCR

    G protein-coupled receptor

    HA

    hemagglutinin

    LP

    lysophospholipid

    LPA

    lysophosphatidic acid

    mrad

    milliradius

    S1P

    sphingosine-1-phosphate

    SPR

    surface plasmon resonance

1

H. Mizuno and Y. Kihara contributed equally to this work.

[S]

The online version of this article (available at http://www.jlr.org) contains a supplement.